Melanoma is an aggressive, highly heterogeneous disease. Targeted therapies and immunotherapies have brought a substantial improvement in overall patient survival, but long-term success of these treatments is hindered by therapy resistance. While a number of molecular mechanisms underlying resistance and approaches to bypass it are under investigation, many challenges remain ahead. During the symposium, you will hear about new models and strategies to investigate key aspects of melanoma progression and metastasis and novel approaches to overcome therapy resistance.
Agenda details to come.
*Symposium held via GoToWebinar.